# Tezepelumab reference antibody

Catalog Number: 176918



### **Product name**

Tezepelumab reference antibody

# **Specificity**

**Human TSLP** 

## **Antibody description**

Anti-TSLP Antibody (Tezepelumab)

## Preparation

Recombinant expression and purified from CHO cells.

### **Formulation**

0.1 M Pro-Ac, 20 mM Arg, pH 5.0

## Storage

-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.

## **Clonality**

Monoclonal


# Ig Type

IgG2

## **Applications**


**ELISA** 

## **Validations**




## **SDS-PAGE**

Anti-TSLP Antibody (tezepelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



#### SEC-HPLC

The purity of Anti-TSLP Antibody (tezepelumab) is 98.64%, determined by SEC-HPLC.




Bioactivity: ELISA


Immobilized human TSLP His at 2 ug/mL can bind Anti-TSLP Antibody (tezepelumab), EC50=0.0518 ug/mL.

# Tezepelumab reference antibody


Catalog Number: 176918







Anti-TSLP Antibody (tezepelumab)-induced FACS Blocking activity was evaluated using TSLPR/IL7R-CHO-K. The IC50 was approximately 0.0802 ug/mL.



## Research in vivo

Tezepelumab reduced levels of IL13 in BALF of OVA asthma model on B-hTSLP/hTSLPR mice. The result showed significant IL13 inhibition effects at 15 mpk.